Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Loretta, Jophlin
NAVIGATE, NCT04365868 / 2019-001983-31: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis	Active, not recruiting	2b	357	Europe, Canada, US, RoW	belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo	Galectin Therapeutics Inc., Galectin Therapeutics Inc	Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis	12/24	12/24
Durham, Theresa
NAVIGATE, NCT04365868 / 2019-001983-31: Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis	Active, not recruiting	2b	357	Europe, Canada, US, RoW	belapectin, GR-MD-02, galactoarabino rhamnogalacturonate, Placebo	Galectin Therapeutics Inc., Galectin Therapeutics Inc	Prevention of Esophageal Varices, NASH - Nonalcoholic Steatohepatitis, Cirrhosis	12/24	12/24
NCT05239468 / 2022-001241-20: Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC	Active, not recruiting	2	60	US	Bezafibrate 100 mg, Bezafibrate 200 mg, Obeticholic Acid 5 mg, Obeticholic Acid placebo, Bezafibrate Placebo	Intercept Pharmaceuticals, Intercept Pharmaceuticals, Inc.	Primary Biliary Cholangitis	11/24	02/25